Exploratory secondary analysis of 127 patients with centrally confirmed advanced papillary RCC in the phase II SUNNIFORECAST trial: 12-month OS was 74.77% with ipilimumab/nivolumab vs 63.44% with standard care (p=0.085, not significant); median OS 24.89 vs 18.88 months.
Secondary analysisn = 127
Ahrens et al. Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review